Loading…

Celcuity Inc.CELCCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Clinical-stage biopharmaceutical company developing gedatolisib and other targeted therapies for breast cancer and solid tumors.

Momentum laggard 11
Mkt cap
$2.73B
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$73.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.4%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · USD$55.60
1D-4.2%
1W-13.6%
1M-7.3%
3M-38.6%
6M-60.4%
YTD-44.3%
1Y-39.7%
ATR %7.5%
Beta1.10
52w lowhigh63.2% off high

What Celcuity does

Clinical-stage biopharmaceutical company developing gedatolisib and other targeted therapies for breast cancer and solid tumors.

Has no approved product, so it is paid for by money raised from investors rather than by sales. Nearly everything hangs on the lead drug, gedatolisib, an intravenous drug that blocks two linked cell-growth signals, which still has to clear regulators. The CELsignia test is a side platform for selecting patients.

Products and services

  • Gedatolisib (breast cancer, Phase 3)
  • CELsignia diagnostic platform

Customers

  • Oncologists
  • Breast cancer patients (via approved therapy)

Where it sits in the supply chain

  • Biotechnology
  • Oncology drug development
  • PI3K/AKT/mTOR pathway inhibitors

What could go right

  • Gedatolisib FDA approval/launch
  • Expansion into additional tumor types

What could go wrong

  • Clinical trial failure risk
  • No approved/commercial product yet

Moat: narrow (IP / patents). Patent-protected lead drug candidate gedatolisib in late-stage trials for HR+/HER2- breast cancer.

Headquarters: Minneapolis, Minnesota · Founded: 2007 · Employees: 155

Named competitors

Celcuity at a glance

Size Celcuity (CELC) is a United States Health Care company (Medical Specialties) with a market value of $2.73B, the 1593rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $55.60 on 18 Nov 2026.

Performance Over six months the shares fell 60.4%, against -1.3% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Credit Celcuity has 1 bond outstanding ($575M).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 100CELC 39
Six months, rebased to 100: Celcuity against the median of its 20 peers (local-currency closes).

Celcuity financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$216,000-$167,000-$129,947-$142,772-$210,918
EBITDA-$243M-$172M-$113M-$66.1M-$39.2M
Net income-$256M-$177M-$112M-$63.8M-$40.4M
Free cash flow-$213M-$154M-$83.7M-$53.9M-$36.2M
Capital expenditure$50.8M$249,000$249,878$97,644$158,768
Total debt$755M$322M$98.0M$37.4M$35.2M

Quarterly statements and history in the cockpit →

Celcuity competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%COTNOBCKATRCEBOMOVE688114002901NEOGAFX300529EKTA-BIRTC3000036880296883012276TMDX603658PLSECELC6-month return →1-month return →
Up and to the right = strong over both horizons. Celcuity is the large dot.

Celcuity competitors and peer comparison

Head to head with its named competitors (CELC vs PFE vs NOVN.SW vs LLY)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Celcuity CELC$2.73B-60%n/an/an/an/a
Pfizer PFE$160B+9%+1%26%3.3×-4.3%
Novartis NOVN.SW$285B+11%-4%30%6.2×1.6%
Lilly (Eli) LLY$1.30T+36%+46%51%15.6×6.5%
Relay Therapeutics RLAY$3.65B+27%+24%-3,095%273.1×n/a

How Celcuity compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Celcuity against its 20 peers (data as of 18 Nov 2026)
MeasureCELCPeer medianRank in peer set
1-month return-7.3%-3.0%8th lowest of 21
6-month return-60.4%-1.3%lowest of 21
Distance from 52-week high-63.2%-30.5%lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Celcuity CELCUnited States$2.73B-60%n/an/an/an/an/a
COMET COTN.SWSwitzerland$2.78B-15%-3%6%5.0×n/an/a
Ottobock SE & Co. KGaA OBCK.DEGermany$2.65B-30%+5%17%2.0×-1.2%+8.0%
AtriCure ATRCUnited States$2.82B+91%+14%3%4.6×54.2%+20.9%
EBOS EBO.AXAustralia$2.50B+7%+3%3%0.4×4.7%+6.8%
Medacta MOVE.SWSwitzerland$2.48B-28%+8%15%3.6×n/an/a
MGI Tech 688114.SSChina$3.06B-4%+2%-7%5.9×43.7%-0.1%
Double Medical Technology 002901.SZChina$2.43B-2%+13%26%5.4×7.6%+10.4%
Neogen NEOGUnited States$2.42B+25%0%0%3.4×n/an/a
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%1.6×12.5%+10.8%
Jafron Biomedical 300529.SZChina$2.35B+3%+1%37%6.8×6.1%+0.6%
Elekta EKTA-B.STSweden$2.35B0%-7%6%1.7×10.7%+4.0%
iRhythm IRTCUnited States$3.19B-19%+22%5%3.9×46.9%+23.0%
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%4.1×8.7%-4.2%
Micro-Tech (Nanjing) 688029.SSChina$2.33B0%+6%18%4.3×11.9%+19.2%
Zhende Medical 603301.SSChina$3.26B-10%+8%7%4.8×22.9%-16.1%
iRay Technology 688301.SSChina$3.31B-30%+58%24%6.9×n/an/a
Shanghai Conant Optical 2276.HKHong Kong$2.25B-17%+8%29%6.2×-1.1%+14.1%
TransMedics TMDXUnited States$3.35B+42%+28%12%5.1×38.4%+88.2%
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%5.0×-0.4%+7.2%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%2,133.8×n/an/a

Celcuity bonds and credit

Celcuity has 1 bond outstanding with $575M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Celcuity's main competitors?
Named competitors: Pfizer (PFE), Novartis (Piqray/alpelisib) (NOVN.SW), Eli Lilly (LLY), Relay Therapeutics (RLAY). The cockpit's measured peer set (industry) also includes COMET (COTN.SW), Ottobock SE & Co. KGaA (OBCK.DE), AtriCure (ATRC), EBOS (EBO.AX), Medacta (MOVE.SW), MGI Tech (688114.SS).
How has Celcuity stock performed?
Over six months to 18 Nov 2026 the shares returned -60.4% against -1.3% for the median peer; over one year -39.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.